Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome
| Autor: | William P. Dole, Jung T, Hanefeld M, Meyer Hf, Rajman I, Michael Bartlett, Wilhelm Krone, Margaret F. Prescott, Ching-Ming Yeh |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Urology Tetrazoles Pharmacology urologic and male genital diseases Plasma renin activity law.invention Renin-Angiotensin System chemistry.chemical_compound Irbesartan Double-Blind Method Fumarates Randomized controlled trial law Renin Renin–angiotensin system Internal Medicine medicine Humans National Cholesterol Education Program Antihypertensive Agents Aged Inflammation Metabolic Syndrome business.industry Biphenyl Compounds Middle Aged Aliskiren medicine.disease Amides Lipids Angiotensin II Treatment Outcome chemistry Cardiovascular Diseases Hypertension Female Metabolic syndrome business medicine.drug |
| Zdroj: | Journal of Human Hypertension. 25:186-195 |
| ISSN: | 1476-5527 0950-9240 |
| Popis: | Metabolic syndrome, a cluster of risk factors that increase the risk of cardiovascular morbidity and mortality, is common in patients with hypertension. Chronic renin–angiotensin–aldosterone system (RAAS) activation, shown by elevated plasma renin activity (PRA), is implicated in many of the features of metabolic syndrome. The direct renin inhibitor aliskiren may be of benefit in this patient group as aliskiren targets the RAAS at the rate-limiting step. In this double-blind study, 141 patients with hypertension (mean baseline BP 155/93 mm Hg) and metabolic syndrome (modified National Cholesterol Education Program ATP III criteria) were randomized to aliskiren 300 mg or irbesartan 300 mg once daily. Patients treated with aliskiren 300 mg had their mean sitting blood pressure (BP) lowered by 13.8/7.1 mm Hg after 12 weeks, significantly greater (P⩽0.001) than the 5.8/2.8 mm Hg reduction observed in patients treated with irbesartan 300 mg. A significantly greater proportion of patients treated with aliskiren achieved BP control to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|